ASTRAZENECA PLC
AZNCFDrugs in Pipeline
303
Phase 3 Programs
188
Upcoming Catalysts
16
Next Catalyst
This month
Market Overview
Stock performance and key metrics
16 upcoming, 4 past
Zibotentan/Dapagliflozin Phase 2 Est. Readout
Estimated primary completion for Zibotentan/Dapagliflozin trial (NCT06942910) in Chronic Kidney Disease With High Proteinuria. Topline data typically follows completion by weeks to months.
Source15 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
candsartan cilexetil
Pediatric Hypertension
Simvastatin
Hypercholesterolemia
Etoposide
Non-small Cell Lung Cancer
Baxdrostat/dapagliflozin
Chronic Kidney Disease and Hypertension
Pemetrexed
NSCLC
Glyburide
Diabetes
Quetiapine fumarate (Seroquel) SR
Affective Psychosis, Bipolar
Seloken ZOK/Toprol-XL
Heart Failure, Congestive
Quetiapine Fumarate (SEROQUEL) Extended Release
Bipolar Depression
Risperidone
Schizophrenia
Budesonide/formoterol (SYMBICORT) pMDI
Asthma
Esomeprazole 40 mg
Gastric Ulcer
Symbicort, used twice daily (b.i.d) and as needed (prn)
Asthma
AZD0120
Relapsed Refractory Multiple Myeloma
Camizestrant
Breast Cancer, Early Breast Cancer
budesonide
Asthma
Tamoxifen
Bone Density
Paclitaxel
Metastatic Breast Cancer
Candesartan
Congestive Heart Failure
Puxitatug Samrotecan
Endometrial Cancer
Ticagrelor
Peripheral Artery Disease
Symbicort pMDI
Asthma
Rosuvastatin calcium
Coronary Arteriosclerosis
pramlintide acetate
Overweight
BDA MDI HFO 160/180 μg
Asthma
Rilvegostomig
Biliary Tract Cancer
Symbicort
Asthma
Domvanalimab
Non-Small Cell Lung Cancer
75mg selumetinib
Metastatic
glimepiride
Type 2 Diabetes Mellitus
biphasic insulin aspart
Diabetes Mellitus, Type 2
AZD9833
Advanced ER-Positive HER2-Negative Breast Cancer
Letrozole
ER-Positive HER2-Negative Breast Cancer
Ranitidine
NSAID Associated Gastric Ulcers
Tralokinumab
Asthma
Budesonide/formoterol Turbuhaler
Asthma
candesartan cilexetil
Type 1 Diabetes
dacarbazine
Melanoma
AZD9291 80 mg/40 mg
Stage IB-IIIA Non-small Cell Lung Carcinoma
AZD0780
Cardiovascular Disease
Anastrozole (Arimidex)
Breast Cancer
savolitinib
Carcinoma
MEDI4736 (Durvalumab)
Advanced Solid Malignancies
Sunitinib
Carcinoma
sitagliptin
Type 2 Diabetes
Carboplatin
Endometrial Cancer
Tozorakimab
Asthma
Metformin XR
Type 2 Diabetes
AZD0486
B-cell Acute Lymphoblastic Leukemia (B-ALL)
methotrexate
Squamous Cell Carcinoma of the Head and Neck
Rosuvastatin 20mg
Homozygous Familial Hypercholesterolemia (HoFH)
Aclidinium bromide
Chronic Obstructive Pulmonary Disease
Aclidinium Bromide/Formoterol Fumarate
Chronic Obstructive Pulmonary Disease (COPD)
Duloxetine
Major Depressive Disorder
Olaparib 300mg tablets
Newly Diagnosed
MEDI4736 (Durvalumab)+Tremelimumab
Non-Small-Cell Lung Carcinoma NSCLC
Exemestane
Locally Advanced Breast Cancer
Symbicort Turbuhaler (Budesonide/formoterol)
Chronic Obstructive Pulmonary Disease
rosiglitazone
Diabetes Mellitus, Type 2
AZD0585
Hypertriglyceridemia
Gefitinib or Docetaxel
Non-Small Cell Lung Cancer
Surovatamig
Untreated Follicular Lymphoma
insulin glargine
Type 2 Diabetes Mellitus
R-mini-CHOP
Large B-cell Lymphoma
Budesonide/formoterol pMDI 40/2.25ug + spacer
Asthma
MEDI4736
Ovarian
Glycopyrronium/Formoterol Fumarate
Chronic Obstructive Pulmonary Disease COPD
D961H sachet 10 mg
Gastric Ulcer (GU)
Budesonide/formoterol pMDI
Chronic Obstructive Pulmonary Disease
Eribulin
Breast Cancer
Volrustomig
Unresectable Pleural Mesothelioma
Docetaxel
Non-Small-Cell Lung Carcinoma
MEDI8897
Respiratory Syncytial Virus Infections
AZD9291
Non-Small Cell Lung Cancer
BFF MDI 160/9.6 μg BID (320/19.2μg/day)
Asthma
Ribociclib
ER-Positive HER2-Negative Breast Cancer
Formoterol Turbuhaler
Chronic Obstructive Pulmonary Disease
Durvalumab + Chemotherapy phase
Advanced or Recurrent Endometrial Cancer
Anastozole (Arimidex)
Breast Cancer
pioglitazone
Type 2 Diabetes Mellitus
Prednisolone
Chronic Obstructive Pulmonary Disease
liraglutide
Type 2 Diabetes Mellitus
AZD9291 Dosing
Lung Cancer
insulin detemir
Type 2 Diabetes Mellitus
Experimental: Tralokinumab
Uncontrolled Asthma
Nab-paclitaxel
Non-small Cell Lung Cancer
Durvalumab (MEDI4736)
Non Small Cell Lung Carcinoma NSCLC
BGF MDI 320/14.4/9.6 μg
COPD (Chronic Obstructive Pulmonary Disease)
Salbutamol
COPD
Dato-DXd
Metastatic Non-small Cell Lung Cancer
TC-5214
Major Depressive Disorder
Fluticasone propionate
Seasonal Allergic Rhinitis
Vinblastine
Urinary Bladder Neoplasms
Open Label Run In Esomeprazole
Gastroesophageal Reflux Disease (GERD)
exenatide twice daily
Type 2 Diabetes Mellitus
NXY-059
Cerebral Stroke
Metoprolol Succinate
High Blood Pressure (Hypertension).
Fulvestrant
Advanced Breast Cancer
Exenatide once weekly suspension
Diabetes Type 2
Elecoglipron
Type 2 Diabetes Mellitus
Ciclesonide Nasal Spray
Rhinitis, Allergic, Seasonal
Tezepelumab
Asthma
Nirsevimab
Lower Respiratory Tract Infection
Experimental: Tezepelumab
Asthma
formoterol
Stable Asthma
Quetiapine Extended Release
Schizophrenia
Tremelimumab
Non Small Cell Lung Cancer NSCLC
enzalutamide
Metastatic Castration-resistant Prostate Cancer
Dapagliflozin 10 mg
Type 2 Diabetes Mellitus
Monalizumab
Squamous Cell Carcinoma of the Head and Neck
Ticagrelor 90 mg
Myocardial Infarction
Aclidinium bromide/formoterol Fixed-Dose Combination
COPD
Gemcitabine
Urothelial Cancer
Foscarnet sodium
HIV Infections
Pravastatin
Hypercholesterolemia
Quetiapine SR
Anxiety Disorders
Biological: Experimental: Tezepelumab
Severe Asthma
Paroxetine
Generalized Anxiety Disorder
AZD2265
Metastatic Castration-resistant Prostate Cancer
MEDI3250
Healthy Japanese Children Age 2 Years Through 6 Years
abiraterone acetate
Metastatic Castration-resistant Prostate Cancer
Capivasertib
Triple Negative Breast Neoplasms
Metformin IR
Diabetes Mellitus, Type 2
Formoterol (OT)
Chronic Obstructive Pulmonary Disease
fostamatinib
Rheumatoid Arthritis
fluticasone
Asthma
Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)
Chronic Obstructive Pulmonary Disease
Anastrozole
Breast Neoplasms
Roflumilast
Asthma
metformin
Type 2 Diabetes Mellitus
SEROQUEL (quetiapine fumarate) Tablets
Bipolar Disorder
Taxane
Breast Cancer; HER2-positive; Metastatic
Rosuvastatin
Aortic Stenosis
Esomeprazole
NSAIDs
Osimertinib
Non-Small Cell Lung Cancer
Formoterol Fumarate
Chronic Obstructive Pulmonary Disease
Exenatide Once Weekly
Type 2 Diabetes Mellitus
Cisplatin
Non-Small Cell Lung Cancer
olaparib
Colorectal Cancer
Dapagliflozin
Type 2 Diabetes Mellitus
Ciclesonide
Asthma
Saxagliptin
Type 2 Diabetes
Quetiapine
Psychotic Disorders
AC2993
Diabetes Mellitus, Non-Insulin-Dependent
Bicalutamide
Prostate Cancer
budesonide/formoterol
Asthma
Quetiapine fumarate
Schizophrenia
Budesonide Turbuhaler (Pulmicort)
Asthma
Saruparib
Metastatic Castration-Sensitive Prostate Cancer
Symbicort Turbuhaler
Asthma
Quetiapine XR
Schizophrenic Disorders
Erlotinib 150/100 mg
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
AZD0901
Gastric Cancer
Ramucirumab+ paclitaxel
Gastric Cancer
Budesonide/formoterol (Symbicort Turbuhaler)
Chronic Obstructive Pulmonary Disease
Selumetinib
Neurofibromatosis 1
AZD7442
COVID-19
Ropivacaine
Anesthesia,Spinal
Chlorambucil
Untreated Chronic Lymphocytic Leukemia
Acalabrutinib
Phase I: Relapsed or Refractory B-cell Malignancies
ARIMIDEX (anastrazole)
Breast Cancer
Terbutaline
Asthma
budesonide (Pulmicort)
Chronic Obstructive Pulmonary Disease
Sodium Zirconium Cyclosilicate (ZS) 5g
Hyperkalemia
HFA MDI
Asthma
Ceralasertib
Advanced or Metastatic NSCLC
Esomeprazole (Nexium)
Gastroesophageal Reflux Disease (GERD)
Durvalumab +Tremelimumab
Non Small Cell Lung Carcinoma NSCLC
Durvalumab
Hepatocellular Carcinoma
Gefitinib
NSCLC
Atorvastatin
Hypercholesterolaemia
Baxdrostat
Primary Hyperaldosteronism
Benralizumab 30 mg SC + Mometasone Furoate
Nasal Polyposis
Sodium Zirconium Cyclosilicate 5g
Hyperkalemia
Datopotamab Deruxtecan
Non-Small Cell Lung Cancer
Capecitabine
Breast Cancer
budesonide/formoterol (Symbicort)
Mild or Moderate Asthma
Seroquel SR
Schizophrenia
NKTR-118
Opioid-Induced Constipation (OIC)
fluticasone/salmeterol
Asthma
Benralizumab
Asthma
Omeprazole
Non-erosive Reflux Disease
Terbutaline Turbuhaler
Asthma
exenatide
Type 2 Diabetes Mellitus
Anifrolumab
Active Systemic Lupus Erythematosus
Lithium
Mania
BGF MDI 320/28.8/9.6 μg
Asthma
Lenvatinib
Hepatocellular Carcinoma
MEDI4736 + Tremelimumab
Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck
gefitinib (IRESSA™, ZD1839)
Breast Cancer
AZD2811
Small-Cell Lung Cancer
Omega-3 carboxylic acids
T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)
Durvalumab / Tremelimumab Combination Therapy
Pediatric Cancer
Vinorelbine
Non-Small-Cell Lung Carcinoma
AZD1419
Asthma
AZD6765 iv
Major Depressive Disorder
Tomudex
Inoperable or Recurrent Rectal Cancer
AZD1656
Type II Diabetes
Arimidex 1 mg
McCune-Albright Syndrome
AZD0837
Persistent or Permanent Non-valvular Atrial Fibrillation
Goserelin acetate
Breast Cancer
AZD1222
COVID-19
AZD6793
Chronic Obstructive Pulmonary Disease (COPD)
AZD8359
Metastatic Prostate Cancer
AZD7798
Moderate to Severe Crohn's Disease
AZD9567
Rheumatoid Arthritis
AZD0865
GERD With Erosive Esophagitis
AZD9750
Prostate Cancer
AZD1305
Left Ventricle Function
AZD3355
Reflux Episodes
AZD7268
Major Depressive Disorder
Quetiapine fumarate (Seroquel)
Major Depressive Disorder
AZD9668
Chronic Obstructive Pulmonary Disease (COPD)
AZD5305
Metastatic Prostate Cancer
AZD1236
Chronic Obstructive Pulmonary Disease
5-FU
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)
AZD7624 1.0 mg
Chronic Obstructive Pulmonary Disease COPD
AZD3480
Alzheimer Disease
LAS100977
Chronic Obstructive Pulmonary Disease (COPD)
Tesaglitazar
Type 2 Diabetes
ZD4054
Non Small Cell Lung Cancer
AZD0292
Bronchiectasis With Pseudomonas Aeruginosa Colonization
AZD6765
Depression
Aclidinium bromide and formoterol
Chronic Obstructive Pulmonary Disease (COPD)
Cediranib
Renal Cell Carcinoma
clopidogrel
Stable Coronary Artery Disease
Gefitinib 250mg
Lung Cancer
AZD4831
Non-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
MEDI0382 100 μg
Type 2 Diabetes
Selumetinib granule formulation
Neurofibromatosis Type 1
MEDI-546
Systemic Lupus Erythematosus
AZD3199
Asthma
AZD2423
Chronic Obstructive Pulmonary Disease
AZD2516, 5 mg
Reflux
AZD2265 (FPI-2265)
Metastatic Prostate Cancer
MEDI3506
Diabetic Kidney Disease
AZD9550
Obesity or Overweight
AZD4547
FGFR Inhibition, Pharmacokinetics, Biomarkers
AZD4635
Progressive Metastatic Castrate-Resistant Prostate Cancer
CP-675,206 (Tremelimumab)
Colorectal Neoplasms
AZD5423
Asthma
Selumetinib+Docetaxel
Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)
AZD2066
Pain
AZD4604
Asthma
AZD5004
Obesity or Overweight
CP-675,206
Carcinoma, Non-small-cell Lung
AZD4573
Relapsed/Refractory Peripheral T-cell Lymphoma
AZD2171
Gastrointestinal Stromal Tumors
Zibotentan/Dapagliflozin
Chronic Kidney Disease With High Proteinuria
Febuxostat
Asymptomatic Hyperuricemia
AZD1386
Pain
AZD2389
Liver Fibrosis
Ciclesonide HFA
Rhinitis, Allergic, Seasonal
FOLFOX
Gastric Cancer
gefitinib (Iressa)
Neoplasms, Squamous Cell
Eplontersen
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
AZD5213 + pregabalin
Diabetic Neuropathy, Painful; Diabetic Neuropathies
RDEA3170
Gout and Asymptomatic Hyperuricemia
AZD1446
Mild to Moderate Alzheimer's Disease
AZD5863
Gastric Cancer
AZD3470
Advanced Solid Tumors That Are MTAP Deficient
AZD4877
Bladder Cancer
AZD5148
Clostridioides Difficile Infection
CIN-107
Hypertension
AZD3632
Acute Lymphoblastic Leukaemia
Adavosertib
Uterine Serous Carcinoma
AZD1981
Chronic Obstructive Pulmonary Disease
MEDI7183 low dose
Ulcerative Colitis
AZD8233
Dyslipidaemia
AZD0530
Ovarian Neoplasms
AZD4144
Sepsis
AZD4956
Solid Tumours
Glipizide
Type II Diabetes Mellitus
AZD0516
Metastatic Prostate Cancer
Acalabrutinib monotherapy
Mantle-cell Lymphoma
MEDI4736 in combination with nab-paclitaxel and gemcitabine
Metastatic Pancreatic Ductal Adenocarcinoma
Atirmociclib
Advanced Breast Cancer
AZD6234
Endocrinology
Datopotamab Deruxtecan (Dato-DXd)
Carcinoma, Non-Small-Cell Lung
AZD7325
Anxiety Disorders
AZD6244
Metastatic Colorectal Cancer
AZD5069
Bronchiectasis
CIN-107 2 mg dosing
Primary Aldosteronism
exenatide once monthly suspension
Type 2 Diabetes
Oleclumab
Non-Small Cell Lung Cancer
AZD9773
Severe Sepsis
Nab-paclitaxel+carboplatin
Non-small Cell Lung Cancer NSCLC
Amivantamab
Non-Small Cell Lung Cancer (NSCLC)
Aclidinium Bromide/Formoterol Fumarate 400/12μg BID
Pulmonary Disease, Chronic Obstructive
AZD8848
Allergic Rhinitis
Zibotentan
Chronic Kidney Disease
Drug: carboplatin
Ovarian Cancer
ZD4054 15 mg
Prostate Cancer
Hydrochlorothiazide
Type 2 Diabetes Mellitus
Venetoclax
Mantle Cell Lymphoma (MCL)
AZD0305
Multiple Myeloma
[18F]AZD4694
Alzheimer's Disease
Verinurad
Heart Failure With Preserved Ejection Fraction (HFpEF)
AZD5672
Rheumatoid Arthritis
AZD2281
Ovarian Carcinoma
Zibotentan + dapagliflozin
Liver Cirrhosis
tralokinumab cohort 1
Idiopathic Pulmonary Fibrosis
Anastrazole
Breast Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
candsartan cilexetil | Phase 3 | Pediatric Hypertension | - | - |
Simvastatin | Phase 3 | Hypercholesterolemia | - | - |
Etoposide | Phase 3 | Non-small Cell Lung Cancer | - | - |
Baxdrostat/dapagliflozin | Phase 3 | Chronic Kidney Disease and Hypertension | - | - |
Pemetrexed | Phase 3 | NSCLC | - | - |
Glyburide | Phase 3 | Diabetes | - | - |
Quetiapine fumarate (Seroquel) SR | Phase 3 | Affective Psychosis, Bipolar | - | - |
Seloken ZOK/Toprol-XL | Phase 3 | Heart Failure, Congestive | - | - |
Quetiapine Fumarate (SEROQUEL) Extended Release | Phase 3 | Bipolar Depression | - | - |
Risperidone | Phase 3 | Schizophrenia | - | - |
Budesonide/formoterol (SYMBICORT) pMDI | Phase 3 | Asthma | - | - |
Esomeprazole 40 mg | Phase 3 | Gastric Ulcer | - | - |
Symbicort, used twice daily (b.i.d) and as needed (prn) | Phase 3 | Asthma | - | - |
AZD0120 | Phase 3 | Relapsed Refractory Multiple Myeloma | - | - |
Camizestrant | Phase 3 | Breast Cancer, Early Breast Cancer | - | - |
budesonide | Phase 3 | Asthma | - | - |
Tamoxifen | Phase 3 | Bone Density | - | - |
Paclitaxel | Phase 3 | Metastatic Breast Cancer | - | - |
Candesartan | Phase 3 | Congestive Heart Failure | - | - |
Puxitatug Samrotecan | Phase 3 | Endometrial Cancer | - | - |
Ticagrelor | Phase 3 | Peripheral Artery Disease | - | - |
Symbicort pMDI | Phase 3 | Asthma | - | - |
Rosuvastatin calcium | Phase 3 | Coronary Arteriosclerosis | - | - |
pramlintide acetate | Phase 3 | Overweight | - | - |
BDA MDI HFO 160/180 μg | Phase 3 | Asthma | - | - |
Rilvegostomig | Phase 3 | Biliary Tract Cancer | - | - |
Symbicort | Phase 3 | Asthma | - | - |
Domvanalimab | Phase 3 | Non-Small Cell Lung Cancer | - | - |
75mg selumetinib | Phase 3 | Metastatic | - | - |
glimepiride | Phase 3 | Type 2 Diabetes Mellitus | - | - |
biphasic insulin aspart | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
AZD9833 | Phase 3 | Advanced ER-Positive HER2-Negative Breast Cancer | - | - |
Letrozole | Phase 3 | ER-Positive HER2-Negative Breast Cancer | - | - |
Ranitidine | Phase 3 | NSAID Associated Gastric Ulcers | - | - |
Tralokinumab | Phase 3 | Asthma | - | - |
Budesonide/formoterol Turbuhaler | Phase 3 | Asthma | - | - |
candesartan cilexetil | Phase 3 | Type 1 Diabetes | - | - |
dacarbazine | Phase 3 | Melanoma | - | - |
AZD9291 80 mg/40 mg | Phase 3 | Stage IB-IIIA Non-small Cell Lung Carcinoma | - | - |
AZD0780 | Phase 3 | Cardiovascular Disease | - | - |
Anastrozole (Arimidex) | Phase 3 | Breast Cancer | - | - |
savolitinib | Phase 3 | Carcinoma | - | - |
MEDI4736 (Durvalumab) | Phase 3 | Advanced Solid Malignancies | - | - |
Sunitinib | Phase 3 | Carcinoma | - | - |
sitagliptin | Phase 3 | Type 2 Diabetes | - | - |
Carboplatin | Phase 3 | Endometrial Cancer | - | - |
Tozorakimab | Phase 3 | Asthma | - | - |
Metformin XR | Phase 3 | Type 2 Diabetes | - | - |
AZD0486 | Phase 3 | B-cell Acute Lymphoblastic Leukemia (B-ALL) | - | - |
methotrexate | Phase 3 | Squamous Cell Carcinoma of the Head and Neck | - | - |
Rosuvastatin 20mg | Phase 3 | Homozygous Familial Hypercholesterolemia (HoFH) | - | - |
Aclidinium bromide | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
Aclidinium Bromide/Formoterol Fumarate | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
Duloxetine | Phase 3 | Major Depressive Disorder | - | - |
Olaparib 300mg tablets | Phase 3 | Newly Diagnosed | - | - |
MEDI4736 (Durvalumab)+Tremelimumab | Phase 3 | Non-Small-Cell Lung Carcinoma NSCLC | - | - |
Exemestane | Phase 3 | Locally Advanced Breast Cancer | - | - |
Symbicort Turbuhaler (Budesonide/formoterol) | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
rosiglitazone | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
AZD0585 | Phase 3 | Hypertriglyceridemia | - | - |
Gefitinib or Docetaxel | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Surovatamig | Phase 3 | Untreated Follicular Lymphoma | - | - |
insulin glargine | Phase 3 | Type 2 Diabetes Mellitus | - | - |
R-mini-CHOP | Phase 3 | Large B-cell Lymphoma | - | - |
Budesonide/formoterol pMDI 40/2.25ug + spacer | Phase 3 | Asthma | - | - |
MEDI4736 | Phase 3 | Ovarian | - | - |
Glycopyrronium/Formoterol Fumarate | Phase 3 | Chronic Obstructive Pulmonary Disease COPD | - | - |
D961H sachet 10 mg | Phase 3 | Gastric Ulcer (GU) | - | - |
Budesonide/formoterol pMDI | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
Eribulin | Phase 3 | Breast Cancer | - | - |
Volrustomig | Phase 3 | Unresectable Pleural Mesothelioma | - | - |
Docetaxel | Phase 3 | Non-Small-Cell Lung Carcinoma | - | - |
MEDI8897 | Phase 3 | Respiratory Syncytial Virus Infections | - | - |
AZD9291 | Phase 3 | Non-Small Cell Lung Cancer | - | - |
BFF MDI 160/9.6 μg BID (320/19.2μg/day) | Phase 3 | Asthma | - | - |
Ribociclib | Phase 3 | ER-Positive HER2-Negative Breast Cancer | - | - |
Formoterol Turbuhaler | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
Durvalumab + Chemotherapy phase | Phase 3 | Advanced or Recurrent Endometrial Cancer | - | - |
Anastozole (Arimidex) | Phase 3 | Breast Cancer | - | - |
pioglitazone | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Prednisolone | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
liraglutide | Phase 3 | Type 2 Diabetes Mellitus | - | - |
AZD9291 Dosing | Phase 3 | Lung Cancer | - | - |
insulin detemir | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Experimental: Tralokinumab | Phase 3 | Uncontrolled Asthma | - | - |
Nab-paclitaxel | Phase 3 | Non-small Cell Lung Cancer | - | - |
Durvalumab (MEDI4736) | Phase 3 | Non Small Cell Lung Carcinoma NSCLC | - | - |
BGF MDI 320/14.4/9.6 μg | Phase 3 | COPD (Chronic Obstructive Pulmonary Disease) | - | - |
Salbutamol | Phase 3 | COPD | - | - |
Dato-DXd | Phase 3 | Metastatic Non-small Cell Lung Cancer | - | - |
TC-5214 | Phase 3 | Major Depressive Disorder | - | - |
Fluticasone propionate | Phase 3 | Seasonal Allergic Rhinitis | - | - |
Vinblastine | Phase 3 | Urinary Bladder Neoplasms | - | - |
Open Label Run In Esomeprazole | Phase 3 | Gastroesophageal Reflux Disease (GERD) | - | - |
exenatide twice daily | Phase 3 | Type 2 Diabetes Mellitus | - | - |
NXY-059 | Phase 3 | Cerebral Stroke | - | - |
Metoprolol Succinate | Phase 3 | High Blood Pressure (Hypertension). | - | - |
Fulvestrant | Phase 3 | Advanced Breast Cancer | - | - |
Exenatide once weekly suspension | Phase 3 | Diabetes Type 2 | - | - |
Elecoglipron | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Ciclesonide Nasal Spray | Phase 3 | Rhinitis, Allergic, Seasonal | - | - |
Tezepelumab | Phase 3 | Asthma | - | - |
Nirsevimab | Phase 3 | Lower Respiratory Tract Infection | - | - |
Experimental: Tezepelumab | Phase 3 | Asthma | - | - |
formoterol | Phase 3 | Stable Asthma | - | - |
Quetiapine Extended Release | Phase 3 | Schizophrenia | - | - |
Tremelimumab | Phase 3 | Non Small Cell Lung Cancer NSCLC | - | - |
enzalutamide | Phase 3 | Metastatic Castration-resistant Prostate Cancer | - | - |
Dapagliflozin 10 mg | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Monalizumab | Phase 3 | Squamous Cell Carcinoma of the Head and Neck | - | - |
Ticagrelor 90 mg | Phase 3 | Myocardial Infarction | - | - |
Aclidinium bromide/formoterol Fixed-Dose Combination | Phase 3 | COPD | - | - |
Gemcitabine | Phase 3 | Urothelial Cancer | - | - |
Foscarnet sodium | Phase 3 | HIV Infections | - | - |
Pravastatin | Phase 3 | Hypercholesterolemia | - | - |
Quetiapine SR | Phase 3 | Anxiety Disorders | - | - |
Biological: Experimental: Tezepelumab | Phase 3 | Severe Asthma | - | - |
Paroxetine | Phase 3 | Generalized Anxiety Disorder | - | - |
AZD2265 | Phase 3 | Metastatic Castration-resistant Prostate Cancer | - | - |
MEDI3250 | Phase 3 | Healthy Japanese Children Age 2 Years Through 6 Years | - | - |
abiraterone acetate | Phase 3 | Metastatic Castration-resistant Prostate Cancer | - | - |
Capivasertib | Phase 3 | Triple Negative Breast Neoplasms | - | - |
Metformin IR | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Formoterol (OT) | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
fostamatinib | Phase 3 | Rheumatoid Arthritis | - | - |
fluticasone | Phase 3 | Asthma | - | - |
Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
Anastrozole | Phase 3 | Breast Neoplasms | - | - |
Roflumilast | Phase 3 | Asthma | - | - |
metformin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
SEROQUEL (quetiapine fumarate) Tablets | Phase 3 | Bipolar Disorder | - | - |
Taxane | Phase 3 | Breast Cancer; HER2-positive; Metastatic | - | - |
Rosuvastatin | Phase 3 | Aortic Stenosis | - | - |
Esomeprazole | Phase 3 | NSAIDs | - | - |
Osimertinib | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Formoterol Fumarate | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
Exenatide Once Weekly | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Cisplatin | Phase 3 | Non-Small Cell Lung Cancer | - | - |
olaparib | Phase 3 | Colorectal Cancer | - | - |
Dapagliflozin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Ciclesonide | Phase 3 | Asthma | - | - |
Saxagliptin | Phase 3 | Type 2 Diabetes | - | - |
Quetiapine | Phase 3 | Psychotic Disorders | - | - |
AC2993 | Phase 3 | Diabetes Mellitus, Non-Insulin-Dependent | - | - |
Bicalutamide | Phase 3 | Prostate Cancer | - | - |
budesonide/formoterol | Phase 3 | Asthma | - | - |
Quetiapine fumarate | Phase 3 | Schizophrenia | - | - |
Budesonide Turbuhaler (Pulmicort) | Phase 3 | Asthma | - | - |
Saruparib | Phase 3 | Metastatic Castration-Sensitive Prostate Cancer | - | - |
Symbicort Turbuhaler | Phase 3 | Asthma | - | - |
Quetiapine XR | Phase 3 | Schizophrenic Disorders | - | - |
Erlotinib 150/100 mg | Phase 3 | Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer | - | - |
AZD0901 | Phase 3 | Gastric Cancer | - | - |
Ramucirumab+ paclitaxel | Phase 3 | Gastric Cancer | - | - |
Budesonide/formoterol (Symbicort Turbuhaler) | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
Selumetinib | Phase 3 | Neurofibromatosis 1 | - | - |
AZD7442 | Phase 3 | COVID-19 | - | - |
Ropivacaine | Phase 3 | Anesthesia,Spinal | - | - |
Chlorambucil | Phase 3 | Untreated Chronic Lymphocytic Leukemia | - | - |
Acalabrutinib | Phase 3 | Phase I: Relapsed or Refractory B-cell Malignancies | - | - |
ARIMIDEX (anastrazole) | Phase 3 | Breast Cancer | - | - |
Terbutaline | Phase 3 | Asthma | - | - |
budesonide (Pulmicort) | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
Sodium Zirconium Cyclosilicate (ZS) 5g | Phase 3 | Hyperkalemia | - | - |
HFA MDI | Phase 3 | Asthma | - | - |
Ceralasertib | Phase 3 | Advanced or Metastatic NSCLC | - | - |
Esomeprazole (Nexium) | Phase 3 | Gastroesophageal Reflux Disease (GERD) | - | - |
Durvalumab +Tremelimumab | Phase 3 | Non Small Cell Lung Carcinoma NSCLC | - | - |
Durvalumab | Phase 3 | Hepatocellular Carcinoma | - | - |
Gefitinib | Phase 3 | NSCLC | - | - |
Atorvastatin | Phase 3 | Hypercholesterolaemia | - | - |
Baxdrostat | Phase 3 | Primary Hyperaldosteronism | - | - |
Benralizumab 30 mg SC + Mometasone Furoate | Phase 3 | Nasal Polyposis | - | - |
Sodium Zirconium Cyclosilicate 5g | Phase 3 | Hyperkalemia | - | - |
Datopotamab Deruxtecan | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Capecitabine | Phase 3 | Breast Cancer | - | - |
budesonide/formoterol (Symbicort) | Phase 3 | Mild or Moderate Asthma | - | - |
Seroquel SR | Phase 3 | Schizophrenia | - | - |
NKTR-118 | Phase 3 | Opioid-Induced Constipation (OIC) | - | - |
fluticasone/salmeterol | Phase 3 | Asthma | - | - |
Benralizumab | Phase 3 | Asthma | - | - |
Omeprazole | Phase 3 | Non-erosive Reflux Disease | - | - |
Terbutaline Turbuhaler | Phase 3 | Asthma | - | - |
exenatide | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Anifrolumab | Phase 3 | Active Systemic Lupus Erythematosus | - | - |
Lithium | Phase 3 | Mania | - | - |
BGF MDI 320/28.8/9.6 μg | Phase 3 | Asthma | - | - |
Lenvatinib | Phase 3 | Hepatocellular Carcinoma | - | - |
MEDI4736 + Tremelimumab | Phase 2 | Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck | - | - |
gefitinib (IRESSA™, ZD1839) | Phase 2 | Breast Cancer | - | - |
AZD2811 | Phase 2 | Small-Cell Lung Cancer | - | - |
Omega-3 carboxylic acids | Phase 2 | T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin) | - | - |
Durvalumab / Tremelimumab Combination Therapy | Phase 2 | Pediatric Cancer | - | - |
Vinorelbine | Phase 2 | Non-Small-Cell Lung Carcinoma | - | - |
AZD1419 | Phase 2 | Asthma | - | - |
AZD6765 iv | Phase 2 | Major Depressive Disorder | - | - |
Tomudex | Phase 2 | Inoperable or Recurrent Rectal Cancer | - | - |
AZD1656 | Phase 2 | Type II Diabetes | - | - |
Arimidex 1 mg | Phase 2 | McCune-Albright Syndrome | - | - |
AZD0837 | Phase 2 | Persistent or Permanent Non-valvular Atrial Fibrillation | - | - |
Goserelin acetate | Phase 2 | Breast Cancer | - | - |
AZD1222 | Phase 2 | COVID-19 | - | - |
AZD6793 | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
AZD8359 | Phase 2 | Metastatic Prostate Cancer | - | - |
AZD7798 | Phase 2 | Moderate to Severe Crohn's Disease | - | - |
AZD9567 | Phase 2 | Rheumatoid Arthritis | - | - |
AZD0865 | Phase 2 | GERD With Erosive Esophagitis | - | - |
AZD9750 | Phase 2 | Prostate Cancer | - | - |
AZD1305 | Phase 2 | Left Ventricle Function | - | - |
AZD3355 | Phase 2 | Reflux Episodes | - | - |
AZD7268 | Phase 2 | Major Depressive Disorder | - | - |
Quetiapine fumarate (Seroquel) | Phase 2 | Major Depressive Disorder | - | - |
AZD9668 | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
AZD5305 | Phase 2 | Metastatic Prostate Cancer | - | - |
AZD1236 | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
5-FU | Phase 2 | Sub-study 1 Cervical Cancer (Volrustomig Monotherapy) | - | - |
AZD7624 1.0 mg | Phase 2 | Chronic Obstructive Pulmonary Disease COPD | - | - |
AZD3480 | Phase 2 | Alzheimer Disease | - | - |
LAS100977 | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
Tesaglitazar | Phase 2 | Type 2 Diabetes | - | - |
ZD4054 | Phase 2 | Non Small Cell Lung Cancer | - | - |
AZD0292 | Phase 2 | Bronchiectasis With Pseudomonas Aeruginosa Colonization | - | - |
AZD6765 | Phase 2 | Depression | - | - |
Aclidinium bromide and formoterol | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
Cediranib | Phase 2 | Renal Cell Carcinoma | - | - |
clopidogrel | Phase 2 | Stable Coronary Artery Disease | - | - |
Gefitinib 250mg | Phase 2 | Lung Cancer | - | - |
AZD4831 | Phase 2 | Non-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosis | - | - |
MEDI0382 100 μg | Phase 2 | Type 2 Diabetes | - | - |
Selumetinib granule formulation | Phase 2 | Neurofibromatosis Type 1 | - | - |
MEDI-546 | Phase 2 | Systemic Lupus Erythematosus | - | - |
AZD3199 | Phase 2 | Asthma | - | - |
AZD2423 | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
AZD2516, 5 mg | Phase 2 | Reflux | - | - |
AZD2265 (FPI-2265) | Phase 2 | Metastatic Prostate Cancer | - | - |
MEDI3506 | Phase 2 | Diabetic Kidney Disease | - | - |
AZD9550 | Phase 2 | Obesity or Overweight | - | - |
AZD4547 | Phase 2 | FGFR Inhibition, Pharmacokinetics, Biomarkers | - | - |
AZD4635 | Phase 2 | Progressive Metastatic Castrate-Resistant Prostate Cancer | - | - |
CP-675,206 (Tremelimumab) | Phase 2 | Colorectal Neoplasms | - | - |
AZD5423 | Phase 2 | Asthma | - | - |
Selumetinib+Docetaxel | Phase 2 | Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV) | - | - |
AZD2066 | Phase 2 | Pain | - | - |
AZD4604 | Phase 2 | Asthma | - | - |
AZD5004 | Phase 2 | Obesity or Overweight | - | - |
CP-675,206 | Phase 2 | Carcinoma, Non-small-cell Lung | - | - |
AZD4573 | Phase 2 | Relapsed/Refractory Peripheral T-cell Lymphoma | - | - |
AZD2171 | Phase 2 | Gastrointestinal Stromal Tumors | - | - |
Zibotentan/Dapagliflozin | Phase 2 | Chronic Kidney Disease With High Proteinuria | - | - |
Febuxostat | Phase 2 | Asymptomatic Hyperuricemia | - | - |
AZD1386 | Phase 2 | Pain | - | - |
AZD2389 | Phase 2 | Liver Fibrosis | - | - |
Ciclesonide HFA | Phase 2 | Rhinitis, Allergic, Seasonal | - | - |
FOLFOX | Phase 2 | Gastric Cancer | - | - |
gefitinib (Iressa) | Phase 2 | Neoplasms, Squamous Cell | - | - |
Eplontersen | Phase 2 | Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | - | - |
AZD5213 + pregabalin | Phase 2 | Diabetic Neuropathy, Painful; Diabetic Neuropathies | - | - |
RDEA3170 | Phase 2 | Gout and Asymptomatic Hyperuricemia | - | - |
AZD1446 | Phase 2 | Mild to Moderate Alzheimer's Disease | - | - |
AZD5863 | Phase 2 | Gastric Cancer | - | - |
AZD3470 | Phase 2 | Advanced Solid Tumors That Are MTAP Deficient | - | - |
AZD4877 | Phase 2 | Bladder Cancer | - | - |
AZD5148 | Phase 2 | Clostridioides Difficile Infection | - | - |
CIN-107 | Phase 2 | Hypertension | - | - |
AZD3632 | Phase 2 | Acute Lymphoblastic Leukaemia | - | - |
Adavosertib | Phase 2 | Uterine Serous Carcinoma | - | - |
AZD1981 | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
MEDI7183 low dose | Phase 2 | Ulcerative Colitis | - | - |
AZD8233 | Phase 2 | Dyslipidaemia | - | - |
AZD0530 | Phase 2 | Ovarian Neoplasms | - | - |
AZD4144 | Phase 2 | Sepsis | - | - |
AZD4956 | Phase 2 | Solid Tumours | - | - |
Glipizide | Phase 2 | Type II Diabetes Mellitus | - | - |
AZD0516 | Phase 2 | Metastatic Prostate Cancer | - | - |
Acalabrutinib monotherapy | Phase 2 | Mantle-cell Lymphoma | - | - |
MEDI4736 in combination with nab-paclitaxel and gemcitabine | Phase 2 | Metastatic Pancreatic Ductal Adenocarcinoma | - | - |
Atirmociclib | Phase 2 | Advanced Breast Cancer | - | - |
AZD6234 | Phase 2 | Endocrinology | - | - |
Datopotamab Deruxtecan (Dato-DXd) | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
AZD7325 | Phase 2 | Anxiety Disorders | - | - |
AZD6244 | Phase 2 | Metastatic Colorectal Cancer | - | - |
AZD5069 | Phase 2 | Bronchiectasis | - | - |
CIN-107 2 mg dosing | Phase 2 | Primary Aldosteronism | - | - |
exenatide once monthly suspension | Phase 2 | Type 2 Diabetes | - | - |
Oleclumab | Phase 2 | Non-Small Cell Lung Cancer | - | - |
AZD9773 | Phase 2 | Severe Sepsis | - | - |
Nab-paclitaxel+carboplatin | Phase 2 | Non-small Cell Lung Cancer NSCLC | - | - |
Amivantamab | Phase 2 | Non-Small Cell Lung Cancer (NSCLC) | - | - |
Aclidinium Bromide/Formoterol Fumarate 400/12μg BID | Phase 2 | Pulmonary Disease, Chronic Obstructive | - | - |
AZD8848 | Phase 2 | Allergic Rhinitis | - | - |
Zibotentan | Phase 2 | Chronic Kidney Disease | - | - |
Drug: carboplatin | Phase 2 | Ovarian Cancer | - | - |
ZD4054 15 mg | Phase 2 | Prostate Cancer | - | - |
Hydrochlorothiazide | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Venetoclax | Phase 2 | Mantle Cell Lymphoma (MCL) | - | - |
AZD0305 | Phase 2 | Multiple Myeloma | - | - |
[18F]AZD4694 | Phase 2 | Alzheimer's Disease | - | - |
Verinurad | Phase 2 | Heart Failure With Preserved Ejection Fraction (HFpEF) | - | - |
AZD5672 | Phase 2 | Rheumatoid Arthritis | - | - |
AZD2281 | Phase 2 | Ovarian Carcinoma | - | - |
Zibotentan + dapagliflozin | Phase 2 | Liver Cirrhosis | - | - |
tralokinumab cohort 1 | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
Anastrazole | Phase 2 | Breast Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in ASTRAZENECA PLC's drug pipeline?→
CatalystAlert tracks 303 drug candidates in ASTRAZENECA PLC's (AZNCF) pipeline across Phase 3, Phase 2. Its lead program is candsartan cilexetil (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ASTRAZENECA PLC's next FDA catalyst?→
ASTRAZENECA PLC's (AZNCF) next tracked catalyst is a Phase 2 expected July 8, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AZNCF biotech catalysts?→
Add AZNCF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ASTRAZENECA PLC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.